Biotech News
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
ir.syndax.com2026-05-06 14:53 EST
NEW YORK , Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the Scrip Awards 2025, held by Citeline.